What Happened?
New York, NY-based Delcath-Systems Appointed Gerard Michel as Chief Executive Officer
About the Company
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company`s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).
About the Person
Gerard Michel is Chief Executive Officer at Delcath Systems. Previously, Gerard held various senior HR leadership roles in the industry.
Info Source
News
Short Profile